Tirzepatide
US$ 24.16
tirzepatide compound pharmacy Injection | Starts at $249/mo Compounded Tirzepatide GLP-1/GIP Care |
Description
Retatrutide is a novel synthetic peptide designed as a triple agonist, targeting GLP-1, GIP, and glucagon receptors
Side effects vary between individuals
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss
The Heavy Price of GLP-1 Drugs reveals how pharmaceutical companies are exploiting the patent system, delaying competition, and driving up costs for patients
